Inhibition of Candida-induced lymphocyte proliferation by antibody to Candida albicans
- PMID: 3531938
Inhibition of Candida-induced lymphocyte proliferation by antibody to Candida albicans
Abstract
Antibodies to Candida albicans do not prevent the occurrence of candidal vulvovaginitis. To determine if antibodies may be involved in enhancing infectivity, the effects of purified rabbit anti-Candida immunoglobulin G (IgG) on the in vitro cellular immune response to this organism was examined. In four individuals, 50 micrograms/mL rabbit anti-Candida IgG, but not control rabbit IgG, inhibited the lymphocyte proliferative response to Candida antigens by a mean of 92.3%. The degree of inhibition was proportional to antibody concentration over a 5-25 micrograms/mL range. Addition of antibody at the initiation of Candida incubation with peripheral blood mononuclear cells or up to 48 hours later led to a 60-83% inhibition; antibody addition 24 hours before Candida caused only a 29% inhibition. Addition of antibody to purified macrophages concomitantly with Candida or after an overnight incubation of macrophages and Candida, both followed by the addition of lymphocytes, demonstrated that the uptake and/or processing of Candida antigens by macrophages and the recognition by lymphocytes of Candida antigen on the macrophage surface were both inhibited by antibody. Candida-specific antibody may enhance the ability of this organism to escape immune destruction.
Similar articles
-
[Degranulation of eosinophils by IgG antibody to Candida antigen].Arerugi. 1999 May;48(5):546-53. Arerugi. 1999. PMID: 10390902 Japanese.
-
Idiotypy of human anti-Candida albicans antibodies: recurrence, presence of a cross-reactive autoanti-idiotypic-like activity, and role in the induction of specific in vitro antibody response.J Immunol. 1987 Jan 15;138(2):417-22. J Immunol. 1987. PMID: 3540120
-
Immunological cross reactivity between Candida albicans and human tissue.J Clin Lab Immunol. 1996;48(1):1-15. J Clin Lab Immunol. 1996. PMID: 10332630
-
Toxicity to Candida albicans mediated by human serum and peripheral blood mononuclear cells.FEMS Immunol Med Microbiol. 2006 Apr;46(3):452-60. doi: 10.1111/j.1574-695X.2006.00063.x. FEMS Immunol Med Microbiol. 2006. PMID: 16553821
-
Antibody response to Candida albicans cell wall antigens.FEMS Immunol Med Microbiol. 2004 Jul 1;41(3):187-96. doi: 10.1016/j.femsim.2004.03.012. FEMS Immunol Med Microbiol. 2004. PMID: 15196567 Review.
Cited by
-
New treatments for vulvovaginal candidiasis.Infect Dis Obstet Gynecol. 1996;4(4):247-54. doi: 10.1155/S1064744996000476. Infect Dis Obstet Gynecol. 1996. PMID: 18476101 Free PMC article. No abstract available.
-
Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity.Infect Immun. 1995 Feb;63(2):547-53. doi: 10.1128/iai.63.2.547-553.1995. Infect Immun. 1995. PMID: 7822020 Free PMC article.
-
Association between atopy and recurrent vaginal candidiasis.Clin Exp Immunol. 2005 Oct;142(1):167-71. doi: 10.1111/j.1365-2249.2005.02891.x. Clin Exp Immunol. 2005. PMID: 16178872 Free PMC article.
-
Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis.Infect Immun. 1993 Oct;61(10):4202-7. doi: 10.1128/iai.61.10.4202-4207.1993. Infect Immun. 1993. PMID: 8406809 Free PMC article.
-
Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis.Infect Immun. 1994 Mar;62(3):1032-8. doi: 10.1128/iai.62.3.1032-1038.1994. Infect Immun. 1994. PMID: 8112837 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources